Corvus Pharmaceuticals

Corvus Pharmaceuticals announced interim data from a Phase 1 trial of soquelitinib in atopic dermatitis, showing favorable safety and efficacy profiles. The trial enrolled 64 patients with moderate to severe atopic dermatitis, with soquelitinib demonstrating significant EASI score reductions compared to placebo. The company also reported $12.7 million in cash proceeds from early exercise of common stock warrants and plans to host a conference call to discuss the results.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

Corvus Pharmaceuticals published preclinical data for soquelitinib in npj Drug Discovery, showing its potential to modulate tumor immunity by suppressing Th2 and Th17 cytokines while sparing Th1 cytokines. The data indicates enhanced CD8+ T cell and memory T cell function. Corvus is conducting Phase 3 and Phase 1 trials for PTCL and atopic dermatitis, with plans for a Phase 1 trial in solid tumors.

Corvus Pharmaceuticals provided Q3 2024 updates on its clinical programs, including advancing soquelitinib trials in PTCL and atopic dermatitis with interim data expected in December. Financial highlights include a cash position of $41.7M as of September 30, 2024, and a Q3 net loss of $40.2M, with R&D expenses increasing to $5.2M. The company expects current cash to fund operations into 2026.

New data presented at SITC 39th Annual Meeting highlights ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms.

The article discusses the importance of enabling JavaScript for optimal app performance.

Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms. The study, led by Dr. Lawrence Fong, showed ciforadenant's efficacy in reducing immunosuppression and enhancing anti-PD1 therapy sensitivity in a murine model, consistent with clinical trial data.

The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.